alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 2 is placed in the separate grouping of parts pertaining to trademarks regulations.

Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 6 is placed in the separate grouping of parts pertaining to trademarks regulations.

Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 7 is placed in the separate grouping of parts pertaining to trademarks regulations.

Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 1 is placed in the separate grouping of parts pertaining to patents regulations.

Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 3 pertaining to both patents and trademarks is placed in the grouping pertaining to patents regulations.

Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 4 is placed in the separate grouping of parts pertaining to patents regulations.

Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 5 is placed in the separate grouping of parts pertaining to patents regulations.

§ 41.110 Filing claim information. ( a ) *Clean copy of claims.* Within 14 days of the initiation of the proceeding, each party must file a clean copy of its involved claims and, if a biotechnology material sequence is a limitation, a clean copy of the sequence.
( b ) *Annotated copy of claims.* Within 28 days of the initiation of the proceeding, each party must: ( 1 ) For each involved claim having a limitation that is illustrated in a drawing or biotechnology material sequence, file an annotated copy of the claim indicating in bold face between braces ({ }) where each limitation is shown in the drawing or sequence.
( 2 ) For each involved claim that contains a means-plus-function or step-plus-function limitation in the form permitted under 35 U.S.C. 112(f), file an annotated copy of the claim indicating in bold face between braces ({ }) the specific portions of the specification that describe the structure, material, or acts corresponding to each claimed function.
( c ) Any motion to add or amend a claim must include: ( 1 ) A clean copy of the claim,
( 2 ) A claim chart showing where the disclosure of the patent or application provides written description of the subject matter of the claim, and
( 3 ) Where applicable, a copy of the claims annotated according to paragraph (b) of this section.
[69 FR 50003, Aug. 12, 2004, as amended at 77 FR 46631, Aug. 6, 2012]
#### § 493.1215 Condition: Hematology.

If the laboratory provides services in the specialty of Hematology, the laboratory must meet the requirements specified in §§ 493.1230 through 493.1256, § 493.1269, and §§ 493.1281 through 493.1299.
#### Elizabeth B. Jenkinson, Plaintiff, *v.*Amelia Harris and Arthur Hammond, as Executors, etc., of Edwin Harris, Deceased, Defendants.

(Supreme Court, Ontario Special Term,

June, 1899.)

Reference of disputed claim against a decedent — Neither the report of the referee nor his allowance of costs against executors are reviewable at Special Term.

Since the amendment made in 1893 to séetion 2718 of the Code of Civil Procedure, the section which provides for the reference of a disputed claim against the estate of a decedent, the report of a referee allowing among other things, costs against executors, upon the ground that they have unreasonably resisted payment of the claim, is not reviewable at Special Term, and it has now no power to confirm either the decision as to costs or the report in general.

*715Motion to confirm the report of a referee upon a claim against executors and for an order that costs be allowed against the defendants’ executors.

George L. Bachman, for motion.

Arthur J. Hammond, opposed.

Dunwelly, J.

Motion at Special Term to confirm report of a referee upon a claim against executors referred under the provisions of section 2718 of the Code of Civil Procedure, and for an order of this court that costs be^allowed against the defendants executors.

The referee’s report allows costs against the executors»upon the ground that the claim was unreasonably resisted.

Since the amendment of 1893 to section 2718, the referee possesses the right to adjudicate upon the question of costs; the reference is given the same standing and authority as a reference in an action and judgment is to be entered upon the report.

.An application to confirm is made unnecessary and the former practice of applying to the court for confirmation is no longer applicable to these references which have been rendered by the amendment the same in effect as the ordinary references in actions upon which judgments are rendered without application to the court, because the referee is empowered to determine the issues and decide the claim in place of the court.

The court cannot review the decision of the referee, consequently the court cannot confirm it.

As to costs, the referee is also authorized by the amendment to decide; and where he does so, his decision cannot be reviewed at Special Term.

It is only in a case where costs are not passed upon by the referee that an application to the court is still proper. Fisher v. Bennett, 21 Misc. Rep. 178.

It follows that the motion must be denied, but without costs.

Motion denied, without costs.
#### § 493.1220 Condition: Oral pathology.

If the laboratory provides services in the subspecialty of Oral pathology, the laboratory must meet the requirements specified in §§ 493.1230 through 493.1256, and §§ 493.1281 through 493.1299.
#### STATE OF CONNECTICUT *v.*GEORGE HARRIS

*Elizabeth M. Inkster,*assistant public defender, in support of the petition.

*Michael L. Regan,*assistant state’s attorney, in opposition.

Decided February 13, 1997

The defendant’s petition for certification for appeal from the Appellate Court (AC 16539) is denied.
§ 493.15 Laboratories performing waived tests. ( a ) *Requirement.* Tests for certificate of waiver must meet the descriptive criteria specified in paragraph (b) of this section.
( b ) *Criteria.* Test systems are simple laboratory examinations and procedures which— ( 1 ) Are cleared by FDA for home use;
( 2 ) Employ methodologies that are so simple and accurate as to render the likelihood of erroneous results negligible; or
( 3 ) Pose no reasonable risk of harm to the patient if the test is performed incorrectly.
( c ) *Certificate of waiver tests.* A laboratory may qualify for a certificate of waiver under section 353 of the PHS Act if it restricts the tests that it performs to one or more of the following tests or examinations (or additional tests added to this list as provided under paragraph (d) of this section) and no others: ( 1 ) Dipstick or Tablet Reagent Urinalysis (non-automated) for the following: ( i ) Bilirubin;
( ii ) Glucose;
( iii ) Hemoglobin;
( iv ) Ketone;
( v ) Leukocytes;
( vi ) Nitrite;
( vii ) pH;
( viii ) Protein;
( ix ) Specific gravity; and
( x ) Urobilinogen.
( 2 ) Fecal occult blood-non-automated;
( 3 ) Ovulation tests—visual color comparison tests for human luteinizing hormone;
( 4 ) Urine pregnancy tests—visual color comparison tests;
( 5 ) Erythrocyte sedimentation rate—non-automated;
( 6 ) Hemoglobin—copper sulfate—non-automated;
( 7 ) Blood glucose by glucose monitoring devices cleared by the FDA specifically for home use;
( 8 ) Spun microhematocrit; and
( 9 ) Hemoglobin by single analyte instruments with self-contained or component features to perform specimen/reagent interaction, providing direct measurement and readout.
( d ) *Revisions to criteria for test categorization and the list of waived tests.* HHS will determine whether a laboratory test meets the criteria listed under paragraph (b) of this section for a waived test. Revisions to the list of waived tests approved by HHS will be published in the Federal Register in a notice with opportunity for comment.
( e ) Laboratories eligible for a certificate of waiver must— ( 1 ) Follow manufacturers' instructions for performing the test; and
( 2 ) Meet the requirements in subpart B, Certificate of Waiver, of this part.
[57 FR 7139, Feb. 28, 1992, as amended at 58 FR 5221, Jan. 19, 1993; 82 FR 48773, Oct. 20, 2017]
**
**Exhibit 32.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO**

**SECTION 906OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)**

In connection with the Annual Report on Form10-K for the year ended December 31, 2021 (the “Report”) of Stone Point Credit Corporation (the “Company”), as filed with the Securities and Exchange Commission on the date hereof, I,Scott Bronner, the Principal Executive Officer of the Company, hereby certify, to the best of my knowledge, that: 

 
 (1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Actof 1934, as amended; and 

 
 (2)
The information contained in the Report fairly presents, in all material respects, the financial condition andresults of operations of the Company. 

 

/s/ Scott Bronner
**Name: Scott Bronner****Date: March 30, 2022**
 
**
### T E X A S C O U R T O F A P P E A L S , T H I R D D I S T R I C T , A T A U S T I N
NO. 03-16-00518- CR
Donny Ray Ybarra, Appellant

v. The State of Texas, App ellee

F ROM TH E DISTRI CT COURT O F MI LAM CO UNTY, 20TH JUDICI AL DISTRICT NO. CR24,9 95, H ONO RAB LE JO HN Y OUNGB LOO D, JUDGE P RESIDING

M E M O R A N D U M O P I N I O N Appellant D o n

n y Ra y Ybar ra seeks to appea l a judgme nt of conviction for ag g rava ted kidnapping
. See Tex. Penal Code § 20.04. The trial court has cer tified that (1) this is a plea- barg ain
case and Ybar

ra has no rig ht of appea l, and (2)Yba rra has waived the rig ht of appea l. Acc ording ly , we dismiss the appea l for wa nt of jurisdiction. See Tex. R. App. P . 25.2(a) (2), ( d).

__________________________________________ Scott K. Field, Just ice Be fore J ustices Pury ear , Pemberton, and F ield Dismissed for Want of J urisdiction Filed: September

14, 2016 Do Not Publish
###### Editorial Note on Part 1

#### Editorial Notes:

1. In Patent and Trademark Office publications and usage the part number is omitted from the numbers of §§ 1.1 to 1.352 and the numbers to the right of the decimal point correspond with the respective rule numbers.

2. For nomenclature changes to part 1, see 68 FR 14335, Mar. 25, 2003; 87 FR 68904, Nov. 17, 2022.

#### § 1.931 Order for *inter partes* reexamination.

(a) If it is found that there is a reasonable likelihood that the requester will prevail with respect to at least one of the claims challenged in the request, the determination will include an order for *inter partes* reexamination of the patent for resolution of the question of whether the requester will prevail.

(b) If the order for *inter partes* reexamination resulted from a petition pursuant to § 1.927, the *inter partes* reexamination will ordinarily be conducted by an examiner other than the examiner responsible for the initial determination under § 1.923.

[65 FR 76777, Dec. 7, 2000, as amended at 76 FR 59058, Sept. 23, 2011]

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 2 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 6 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 7 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 1 is placed in the separate grouping of parts pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 3 pertaining to both patents and trademarks is placed in the grouping pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 4 is placed in the separate grouping of parts pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 5 is placed in the separate grouping of parts pertaining to patents regulations.
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<CIK> 0000730212
<NAME> First Capital Institutional Real Estate, Ltd. - 1
<MULTIPLIER> 1
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                      DEC-31-1995
<PERIOD-START>                         JAN-01-1995
<PERIOD-END>                           SEP-30-1995
<CASH>                                   4,197,900
<SECURITIES>                                     0
<RECEIVABLES>                               53,200
<ALLOWANCES>                                     0     
<INVENTORY>                                      0     
<CURRENT-ASSETS>                         4,251,100     
<PP&E>                                  36,889,000     
<DEPRECIATION>                          11,649,100     
<TOTAL-ASSETS>                          29,503,700     
<CURRENT-LIABILITIES>                      878,300     
<BONDS>                                          0     
<COMMON>                                         0     
<PREFERRED-MANDATORY>                            0      
<PREFERRED>                                      0      
<OTHER-SE>                              28,153,000     
<TOTAL-LIABILITY-AND-EQUITY>            29,503,700      
<SALES>                                          0     
<TOTAL-REVENUES>                         3,678,000     
<CGS>                                            0      
<TOTAL-COSTS>                            1,738,500      
<OTHER-EXPENSES>                           172,500     
<LOSS-PROVISION>                                 0     
<INTEREST-EXPENSE>                               0     
<INCOME-PRETAX>                            885,100     
<INCOME-TAX>                                     0     
<INCOME-CONTINUING>                        885,100      
<DISCONTINUED>                                   0     
<EXTRAORDINARY>                                  0     
<CHANGES>                                        0      
<NET-INCOME>                               885,100     
<EPS-PRIMARY>                                15.93        
<EPS-DILUTED>                                15.93      
        
                                  




</TABLE>
§ 1.465 Incompetent and deceased patients. ( a ) *Incompetent patients other than minors.* In the case of a patient who has been adjudicated as lacking the capacity, for any reason other than insufficient age, to manage his or her own affairs, any consent which is required under §§ 1.460 through 1.499 of this part may be given by a court appointed legal guardian.
( b ) *Deceased patients* — ( 1 ) *Vital statistics.* Sec. 1.460 through 1.499 of this part do not restrict the disclosure of patient identifying information relating to the cause of death of a patient under laws requiring the collection of death or other vital statistics or permitting inquiry into the cause of death.
( 2 ) *Consent by personal representative.* Any other disclosure of information identifying a deceased patient as being treated for drug abuse, alcoholism or alcohol abuse, infection with the HIV, or sickle cell anemia is subject to §§ 1.460 through 1.499 of this part. If a written consent to the disclosure is required, the Under Secretary for Health or designee may, upon the prior written request of the next of kin, executor/executrix, administrator/administratrix, or other personal representative of such deceased patient, disclose the contents of such records, only if the Under Secretary for Health or designee determines such disclosure is necessary to obtain survivorship benefits for the deceased patient's survivor. This would include not only VA benefits, but also payments by the Social Security Administration, Worker's Compensation Boards or Commissions, or other Federal, State, or local government agencies, or nongovernment entities, such as life insurance companies.
( 3 ) *Information related to sickle cell anemia.* Information related to sickle cell anemia may be released to a blood relative of a deceased veteran for medical follow-up or family planning purposes.
[60 FR 63929, Dec. 13, 1995, as amended at 85 FR 64043, Oct. 9, 2020]
§ 88.5 Application process—WTC responders. ( a ) An application to the WTC Health Program based on the criteria in § 88.4 must be submitted with documentation of the applicant's employment affiliation (if relevant) and work activity during the dates, times, and locations specified in § 88.4 ( 1 ) Documentation may include but is not limited to a pay stub; official personnel roster; a written statement, under penalty of perjury by an employer; site credentials; or similar documentation.
( 2 ) An applicant who is unable to submit the required documentation must instead offer a written explanation of how he or she tried to obtain proof of presence, residence, or work activity and why the attempt was unsuccessful. The applicant must attest, under penalty of perjury, that he or she meets the criteria specified in § 88.4.
( b ) The application and supporting documentation must be submitted to the WTC Health Program for consideration.
( c ) The WTC Health Program will notify the applicant in writing (or by email if an email address is provided by the applicant) of any deficiencies in the application or the supporting documentation.
§ 102.26 Special procedures: Medical records. ( a ) No response to any request for access to medical records by an individual will be issued by the Privacy Officer for a period of seven working days (*i.e.*, excluding Saturdays, Sundays, and legal public holidays) from the date of receipt.
( b ) USPTO has published as a routine use, for all systems of records containing medical records, consultations with an individual's physician or psychologist if, in the sole judgment of USPTO, disclosure could have an adverse effect upon the individual. The mandatory waiting period set forth in paragraph (a) of this section will permit exercise of this routine use in appropriate cases. USPTO will pay no cost of any such consultation.
( c ) In every case of a request by an individual for access to medical records, the Privacy Officer shall: ( 1 ) Inform the individual of the waiting period prescribed in paragraph (a) of this section;
( 2 ) Obtain the name and address of the individual's physician and/or psychologist, if the individual consents to give them;
( 3 ) Obtain specific, written consent for USPTO to consult the individual's physician and/or psychologist in the event that USPTO believes such consultation is advisable, if the individual consents to give such authorization;
( 4 ) Obtain specific, written consent for USPTO to provide the medical records to the individual's physician or psychologist in the event that USPTO believes access to the record by the individual is best effected under the guidance of the individual's physician or psychologist, if the individual consents to give such authorization; and
( 5 ) Forward the individual's medical record to USPTO's medical expert for review and a determination on whether consultation with or transmittal of the medical records to the individual's physician or psychologist is warranted. If the consultation with or transmittal of such records to the individual's physician or psychologist is determined to be warranted, USPTO's medical expert shall so consult or transmit. Whether or not such a consultation or transmittal occurs, USPTO's medical officer shall provide instruction to the Privacy Officer regarding the conditions of access by the individual to his or her medical records.
( d ) If an individual refuses in writing to give the names and consents set forth in paragraphs (c)(2) through (c)(4) of this section and USPTO has determined that disclosure could have an adverse effect upon the individual, USPTO shall give the individual access to said records by means of a copy, provided without cost to the requester, sent registered mail return receipt requested.
Exhibit 31.1

CERTIFICATION PURSUANT TOSECTION 302 OFTHE SARBANES-OXLEY ACT OF 2002

I, Ralph del Campo, certify that:

|  
|--
|1.
|  
|2.
|  
|3.
|  
|4.

|   
|---
|(a)
|   
|(b)
|   
|(c)
|   
|(d)

|  
|--
|5.

|   
|---
|(a)
|   
|(b)

|             |  |  |  |                                                                    
|------------ |  |  |  | -------------------------------------------------------------------
|             |  |  |  | /s/ RALPHDELCAMPO                                                  
|May 10, 2010 |  |  |  | Ralph del CampoChief Operating Officer(Principal Executive Officer)



---
###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 2 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 6 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 7 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 1 is placed in the separate grouping of parts pertaining to patents regulations.

###### Editorial Note on Part 2

#### Editorial Note:

Nomenclature changes to part 2 appear at 68 FR 14337, Mar. 25, 2003.

#### § 2.156 Not subject to opposition; subject to cancellation.

The published mark is not subject to opposition, but is subject to petitions to cancel as specified in § 2.111 and to cancellation for failure to file the affidavit or declaration required by section 8 of the Act.

[64 FR 48924, Sept. 8, 1999]

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 3 pertaining to both patents and trademarks is placed in the grouping pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 4 is placed in the separate grouping of parts pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 5 is placed in the separate grouping of parts pertaining to patents regulations.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Commodity Futures Trading Commission

# Agency Holding the Meeting:

Commodity Futures Trading Commission.

# Time and Date:

11 a.m., Friday, October 2, 2009.

# Place:

1155 21st St., NW., Washington, DC, 9th Floor Commission Conference Room.

# Status:

Closed.

# Matters to be Considered:

Surveillance Matters.

# Contact Person for More Information:

Sauntia S. Warfield, 202-418-5084.

Sauntia S. Warfield,

Assistant Secretary of the Commission.

[FR Doc. E9-22894 Filed 9-18-09; 4:15 pm]

BILLING CODE 6351-01-P